Key Takeaways
- Four deaths linked to the Oxevision monitoring system have raised concerns about patient safety and privacy.
- Some staff reportedly relied too heavily on the technology, neglecting necessary in-person checks of patients.
- The efficacy of Oxevision lacks independent verification, with critics highlighting conflicts of interest in supporting research.
Incident Overview
In July 2022, 18-year-old Morgan-Rose Hart died at a mental health unit in Essex, marking one of four fatalities associated with the Oxevision patient surveillance system. The inquest revealed that necessary checks were missed, with records improperly documented and patient assessments insufficiently conducted. Hart, who had a history of mental health struggles exacerbated by bullying, was found unresponsive in the bathroom after staff reset an alert instead of performing an in-person check.
Oxevision, developed by Oxehealth, a spin-off from Oxford University, is designed to monitor patients’ breathing and pulse rates remotely. It is used in almost half of England’s mental health trusts and reported approximately £4.7 million in revenue for 2023. However, questions have arisen regarding the reliance on the system, which some staff members appear to utilize instead of direct patient observation. Critics argue this could lead to increased distress among patients, particularly those sensitive to surveillance.
Sophina, a patient monitored by Oxevision, described the psychological impact of constant observation, expressing fear and trauma related to the persistent presence of the camera. Advocacy groups, such as Stop Oxevision, have called for a halt to the technology’s deployment, voicing concerns about consent and patient welfare.
Several other cases corroborate these worries. Michael Nolan, 63, died under similar circumstances at Basildon Hospital, with the inquest revealing inadequate training in using Oxevision among staff. Also, 27-year-old Sophie Alderman reported distress caused by the surveillance system before her death, stating that the technology severely affected her mental state. Her mother echoed this sentiment, highlighting invasions of privacy and insufficient staff training.
Regulatory bodies, including the Care Quality Commission, raised alarms regarding monitoring practices reliant on Oxevision, pointing to incidents where patients’ needs were overlooked. An investigation into Oxevision by the National Institute for Health and Care Research concluded that studies did not sufficiently demonstrate positive outcomes, noting conflicts of interest tied to Oxehealth employees involved in research.
Oxehealth’s founder, Lord Tarassenko, defended the technology, claiming no evidence connects Oxevision’s use to any patient deaths. The system is marketed as enhancing safety while maintaining adherence to NHS England digital technology guidelines that emphasize patient consent. Authorities, including NHS England, have stated any visual monitoring should align with humane care practices.
As scrutiny mounts, the Lampard inquiry, investigating mental health patient deaths under NHS care, is urged to evaluate the role of Oxevision in these tragic incidents. Calls for thorough assessment of the system highlight the need to balance innovation with ethical treatment in mental health care settings.
The content above is a summary. For more details, see the source article.
